Key result
Once-daily subcutaneous bemiparin was superior to intravenous unfractionated heparin for venographic reduction in thrombus size at day 14 (72% vs 52%; P=0.004 for superiority).
Why the study?
Does bemiparin improve venographic reduction in thrombus size compared to unfractionated heparin in patients with acute deep vein thrombosis?
RCT (n=378)
randomised
Yes
Does bemiparin improve venographic reduction in thrombus size compared to unfractionated heparin in patients with acute deep vein thrombosis?
Absolute Event Rate: 72% vs 52%
Absolute Risk Reduction: 20%
p-value: p=0.00003 for non-inferiority, 0.004 for superiority
Bemiparin is superior to unfractionated heparin in reducing thrombus size during the acute phase of deep vein thrombosis treatment, with similar safety and efficacy for recurrence.
No takes yet. Share an insight, caveat, or question.
Supports bemiparin over IV heparin for acute DVT thrombus reduction; extends RCT evidence for LMWH superiority on venographic outcomes.
Gebska et al. (2003) conducted an RCT in acute deep vein thrombosis (n=378). Bemiparin vs. Intravenous unfractionated heparin was evaluated on Venographic reduction in thrombus size assessed objectively on day 14 (p=0.00003 for non-inferiority, 0.004 for superiority). Once-daily subcutaneous bemiparin was superior to intravenous unfractionated heparin for venographic reduction in thrombus size at day 14 (72% vs 52%; P=0.004 for superiority).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: